Analyst Ratings for Auxilium Pharmaceuticals (AUXL)
AUXL Rating Summary
AUXL Price Target Summary
- Highest: $37.00 (Aegis Capital)
- Lowest: $13.00 (Brean Capital)
- Average: $25.54
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$25.54 (+50.6%)
Avg. $ Target:
$25.54 (+50.6%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/14/2013 | Mizuho Securities | New Coverage | Buy (N/A) |
28.00 (N/A) |
16.96 | 16.96 | 0% | Details |
| 6/5/2013 | Leerink Swann | Upgrade | Outperform (Market Perform) |
21.00 (16.00) |
14.82 | 16.96 | 14.44% | Details |
| 5/3/2013 | Morgan Stanley | Upgrade | Equalweight (Underweight) |
N/A (N/A) |
14.66 | 16.96 | 15.69% | Details |
| 4/30/2013 | Stifel Nicolaus | Upgrade | Buy (Hold) |
N/A (N/A) |
14.00 | 16.96 | 21.14% | Details |
| 10/8/2012 | WallachBeth Capital | New Coverage | Buy (N/A) |
32.00 (N/A) |
24.50 | 16.96 | -30.78% | Details |
| 8/16/2012 | Aegis Capital | New Coverage | Buy (N/A) |
37.00 (N/A) |
24.26 | 16.96 | -30.09% | Details |
| 8/1/2012 | MKM Partners | Downgrade | Neutral (Buy) |
N/A (N/A) |
26.94 | 16.96 | -37.05% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 8/1/2012 |
New Coverage | Buy (N/A) |
33.00 (27.00) |
18.50 | 16.96 | -8.32% | Details |
| 1/18/2012 | RBC Capital | Upgrade | Outperform (N/A) |
26.00 (N/A) |
19.73 | 16.96 | -14.04% | Details |
| 10/19/2011 | Collins Stewart | Upgrade | Buy (N/A) |
23.00 (N/A) |
16.60 | 16.96 | 2.17% | Details |
| 10/6/2011 | ThinkEquity | New Coverage | Sell (N/A) |
13.00 (N/A) |
14.37 | 16.96 | 18.02% | Details |
| 9/28/2011 | Citi | Upgrade | Buy (N/A) |
25.00 (N/A) |
14.51 | 16.96 | 16.88% | Details |
| 4/15/2011 | UBS » Updated 8/21/2012 |
New Coverage | Buy (N/A) |
34.00 (32.00) |
22.44 | 16.96 | -24.42% | Details |
| 7/6/2010 | Oppenheimer » Updated 6/14/2012 |
Downgrade | Perform (N/A) |
N/A (N/A) |
21.46 | 16.96 | -20.97% | Details |
